PANW vs PFE: Which Is the Better Buy?
Side-by-side comparison of Palo Alto Networks, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Palo Alto Networks, Inc. · Technology
$287.78
+2.9% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PANW has more upside to fair value
(+2.9%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PANW |
PFE |
| Current Price |
$287.78 |
$25.22 |
| Fair Value Estimate |
$296.19 |
$25.92 |
| Upside to Fair Value |
+2.9%
|
+2.8%
|
| Market Cap |
$196.1B |
$143.7B |
| Forward P/E |
248.9x
|
19.2x
|
| EV / EBITDA |
85.9x
|
12.3x
|
| Price / Sales |
18.5x
|
2.3x
|
| Price / FCF |
45.7x
|
15.2x
|
| Revenue Growth YoY |
+31.1%
|
+5.4%
|
| Gross Margin |
71.9%
|
69.3%
|
| Operating Margin |
9.6%
|
23.4%
|
| Return on Equity |
6.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.19%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Palo Alto Networks is a leading cybersecurity company specializing in next-generation security platforms with a strong subscription and support revenue base comprising approximately 81% of total revenue. The company benefits from a wide and expanding competitive moat driven by its AI- and platform-driven cybersecurity solutions, led by a seasoned management team. Despite strong revenue growth of …
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
PANW |
PFE |
| Zone Low |
$222.14 |
$19.44 |
| Zone High |
$251.76 |
$22.03 |
| In Buy Zone? |
No
|
No
|